Two Phase 3 Trials of Lebrikizumab for Moderate-to-Severe Atopic Dermatitis
New England Journal of Medicine · 23.03.2023 · 388 (12) · 1080-1091
DOI: 10.1056/nejmoa2206714 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift New England Journal of Medicine, erschienen am 23.03.2023. Verfasst von Jonathan I Silverberg und 12 weiteren Autor:innen. Beteiligte Einrichtung: From the Department of Dermatology, George Washington University School of Medicine and Health Sciences, Washington, DC (J.I.S.); the Department of D…. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Dermatitis, Atopic. Die Arbeit wurde bisher 358-mal zitiert (Crossref) und nennt 53 Literaturangaben. Gefördert von: Dermira, a wholly owned subsidiary of Eli Lilly, Dermira Inc..
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- From the Department of Dermatology, George Washington University School of Medicine and Health Sciences, Washington, DC (J.I.S.); the Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York (E.G.-Y.…
Förderung
- Dermira, a wholly owned subsidiary of Eli Lilly
- Dermira Inc.
Zitieren
APA
Silverberg, J. I., Guttman-Yassky, E., Thaçi, D., Irvine, A. D., Stein Gold, L., Blauvelt, A., Simpson, E. L., Chu, C. Y., Liu, Z., Gontijo Lima, R., Pillai, S. G., Seneschal, J., & ADvocate1 and ADvocate2 Investigators (2023). Two Phase 3 Trials of Lebrikizumab for Moderate-to-Severe Atopic Dermatitis. New England Journal of Medicine, 388(12), 1080-1091. https://doi.org/10.1056/nejmoa2206714
Vancouver
Silverberg JI, Guttman-Yassky E, Thaçi D, Irvine AD, Stein Gold L, Blauvelt A, et al. Two Phase 3 Trials of Lebrikizumab for Moderate-to-Severe Atopic Dermatitis. New England Journal of Medicine. 2023;388(12):1080-1091. doi:10.1056/nejmoa2206714
BibTeX
@article{Silverberg2023,
author = {Silverberg, Jonathan I and Guttman-Yassky, Emma and Thaçi, Diamant and Irvine, Alan D and Stein Gold, Linda and Blauvelt, Andrew and Simpson, Eric L and Chu, Chia-Yu and Liu, Zhuqing and Gontijo Lima, Renata and Pillai, Sreekumar G and Seneschal, Julien and ADvocate1 and ADvocate2 Investigators, ADvocate1 and ADvocate2 Investigators},
title = {Two Phase 3 Trials of Lebrikizumab for Moderate-to-Severe Atopic Dermatitis},
journal = {New England Journal of Medicine},
year = {2023},
volume = {388},
number = {12},
pages = {1080--1091},
doi = {10.1056/nejmoa2206714}
}
EUVIMED